<DOC>
	<DOCNO>NCT01868529</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare pharmacodynamic ( effect investigate drug body ) response insulin degludec ( insulin 454 ) insulin glargine steady-state condition subject type 1 diabetes mellitus .</brief_summary>
	<brief_title>Comparison Insulin Degludec With Insulin Glargine Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) treat insulin least 12 month Subject consider generally healthy , except underlie diabetes mellitus relate morbidity ( well control hypertension dyslipidaemia ) base assessment medical history , physical examination clinical laboratory data , judge Investigator Body Mass Index ( BMI ) 18.0 28.0 kg/m^2 ( inclusive ) Glycosylated haemoglobin ( HbA1c ) equal 10.0 % base central laboratory result Subject daily basal insulin requirement 0.2 IU/kg/day 0.6 IU/kg/day allow participate trial . Current total daily treatment insulin must less 1.2 U/kg/day Known suspect allergy trial product ( ) relate product Subject participate trial involve investigational product within 3 month precede start dose Subject donate blood plasma past month excess 500 mL within 12 week precede screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>